Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
58 hedge funds and large institutions have $84.5M invested in Aegerion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 31 reducing their positions, and 16 closing their positions.
119% more capital invested
Capital invested by funds: $38.5M → $84.5M (+$46M)
78% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $708K
18% less funds holding
Funds holding: 71 → 58 (-13)
61% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 31
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$853K |
| 2 |
BC
Broadfin Capital
New York
|
+$608K |
| 3 |
Renaissance Technologies
New York
|
+$601K |
| 4 |
Citigroup
New York
|
+$93.5K |
| 5 |
FMA
FNY Managed Accounts
New York
|
+$50.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$686K |
| 2 |
SIM
Spark Investment Management
New York
|
-$476K |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$382K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$227K |
| 5 |
Two Sigma Investments
New York
|
-$144K |
AEGR Hedge Fund Activity: Q3 2016 in Review
58 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q3 2016, worth a combined $84.5M — up 119% from $38.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AEGR and 3 opened new positions — a net loss of 13 holders — while 31 trimmed existing stakes and 12 added.
The largest buyer was Armistice Capital, adding an estimated $853K. The largest seller was K2 Principal Fund, cutting an estimated $686K.
- 58 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q3 2016, down from 71 in Q2 2016.
- Funds reported $84.5M of Aegerion Pharmaceuticals stock for Q3 2016, up 119% quarter-over-quarter.
- 3 funds opened new Aegerion Pharmaceuticals positions in Q3 2016 and 16 closed out, a net change of -13 holders.
- The largest Aegerion Pharmaceuticals buyer in Q3 2016 was Armistice Capital, an estimated $853K added.
- The largest Aegerion Pharmaceuticals seller in Q3 2016 was K2 Principal Fund, an estimated $686K sold.
Based on aggregated 13F filings for Q3 2016.